Esmaeel G. Gojani
Lethbridge, AB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Serotonergic psychedelics as epigenetic modulators: A paradigm shift in Alzheimer's disease therapeutics.
Journal: Neuroscience and biobehavioral reviews
Published: November 13, 2025
Psilocybin alleviates high-glucose and high-lipid-induced skin aging in BJ5Ta fibroblasts.
Journal: Biochemistry and cell biology = Biochimie et biologie cellulaire
Published: October 17, 2025
Pyruvate kinase M2 in Alzheimer's disease: from dysregulation to therapeutic inhibition.
Journal: Brain communications
Published: September 23, 2025
The Impact of Major and Minor Phytocannabinoids on the Maintenance and Function of INS-1 β-Cells Under High-Glucose and High-Lipid Conditions.
Journal: Molecules (Basel, Switzerland)
Published: January 18, 2025
LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 30, 2024
Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.
Journal: International journal of molecular sciences
Published: December 02, 2024
Anti-Inflammatory Properties of Eugenol in Lipopolysaccharide-Induced Macrophages and Its Role in Preventing β-Cell Dedifferentiation and Loss Induced by High Glucose-High Lipid Conditions.
Journal: Molecules (Basel, Switzerland)
Published: October 25, 2023
Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages.
Journal: Molecules (Basel, Switzerland)
Published: August 17, 2023
Showing 1-9 of 9
Last Updated: 09/26/2026